As Healio previously reported, findings from a real-world electronic medical record study found adults with obesity using tirzepatide (Zepbound, Eli Lilly) were more likely to lose 5%, 10% or 15% of their body weight than those using semaglutide (Wegovy, Novo Nordisk)
This doesnt require precise tracking but does mean being aware that dramatic swings in dietary sodium will show up on the scale and in how your body feels
Factors fueling this expansion include rising demand for weight management therapies, advancements in peptide drug innovation, and the focus on chronic disease management and personalized medicine
Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor
Traditionally, valproic acids clinical effects have been attributed to sodium channel blockade, potentiating GABA, and effects on glutamate/NMDA inhibition